Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCB101 in combination with multiple agents in advanced solid tumors
NCT06771622Phase 2Active, not recruiting
- Sponsor
- FBD Biologics Limited
- Start
- Mar 2025
- Primary completion
- Jan 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of HCB-101 in gastric cancer (GC), colorectal cancer (CRC), triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), ovarian cancer, sponsored by FBD Biologics Limited. Started Mar 2025; status: active, not recruiting.
02
Drugs
HCB-101
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)triple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)ovarian cancer
Beyond the preview
Go deeper on NCT06771622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771622.